An Early Phase 1 interventional study of exosome injection and standard comprehensive internal medical treatment, in Acute-on-Chronic Liver Failure (ACLF), sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University — 6 open to participants now, 8 under way, none of them phase 3. Acute-On-Chronic Liver Failure · Third Affiliated Hospital, Sun Yat-Sen University.
Among the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 1, and was the 12th registered.
167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.
Browse Acute-On-Chronic Liver Failure studies →6 of the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–70
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 20–60
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–65
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–65
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 12–65
By country, each count listing its studies:
Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 4 1
First in 2019; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 20 is below the median of 73 across 96 interventional studies indexed under Acute-On-Chronic Liver Failure.
Median enrollment 60 across the 11 interventional studies, 250 across the 2 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Third Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 134 studies on the registry; 35 are open to participants now.
3 of the studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06996392Third Affiliated Hospital, Sun Yat-Sen UniversityPhase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure | 2026-12-31 |
| NCT07409259Third Affiliated Hospital, Sun Yat-Sen UniversityPT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure | 2027-08-31 |
| NCT06562803Third Affiliated Hospital, Sun Yat-Sen UniversityEfficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this single-center, prospective, randomized controlled study is to evaluate the safety and efficacy of PT-MSCs Exosome Injection (code: PT-MSCs-EVS-2023-1) in treating patients with acute-on-chronic liver failure (ACLF). As an exploratory study with a small sample size, the primary focus is to observe safety outcomes and preliminary efficacy. The study will enroll patients aged 18 to 65 years who meet the diagnostic criteria for acute-on-chronic liver failure as outlined in the 2024 Chinese Liver Failure Clinical Guidelines and have a COSSH-ACLF II score of less than 7.4.
The main questions this study aims to answer are:
Does the combined therapy improve the 12-week survival rate compared to standard treatment alone? What is the safety profile of the PT-MSCs Exosome Injection (incidence of adverse events and serious adverse events)? Does the treatment improve clinical symptoms (such as fatigue, anorexia, and jaundice) and biochemical markers (liver function, coagulation, inflammation)? Does the treatment improve the 4-week survival rate and reduce the incidence of adverse outcomes (death, treatment abandonment, or liver transplantation)?
Participants will be recruited and screened to ensure eligibility. A total of 20 eligible participants will be randomly allocated into one of two groups in a 1:1 ratio using block randomization:
Control Group (10 patients): Participants will receive standard comprehensive internal medical treatment, including antiviral therapy, hepatoprotective drugs, and symptomatic support. Artificial liver support or liver transplantation may be performed based on the investigator's clinical judgment.
Study Group (10 patients): In addition to the standard treatment received by the control group, participants will receive PT-MSCs Exosomes (2×10\^11 particles per dose).
For the Study Group, the exosome injection is diluted in 100 mL of normal saline and administered via intravenous infusion over a period of not less than 2 hours. Treatment is administered once every 3 days (on Day 1, Day 4, Day 7, and Day 10) for a total of 4 doses. All participants will undergo follow-up assessments at specific intervals (Days 4, 7, 10, 13, 28, and 84) to monitor survival, clinical improvement, and safety signals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive standard comprehensive internal medical treatment, including antiviral therapy, hepatoprotective drugs, and symptomatic support. Artificial liver support or liver transplantation may be performed based on the investigator's clinical judgment.
Combination Product: standard comprehensive internal medical treatment,
In addition to the standard treatment received by the control group, participants will receive PT-MSCs Exosomes (2×10\^11 particles per dose).
Biological: exosome injection · Combination Product: standard comprehensive internal medical treatment,
For the Study Group, the exosome injection is diluted in 100 mL of normal saline and administered via intravenous infusion over a period of not less than 2 hours. Treatment is administered once every 3 days (on Day 1, Day 4, Day 7, and Day 10) for a total of 4 doses.
Participants will receive standard comprehensive internal medical treatment, including antiviral therapy, hepatoprotective drugs, and symptomatic support.
12-Week Survival Rate
The percentage of participants who are alive at 12 weeks after enrollment.
Time frame: 12 weeks
Changes from the baseline in COSSH-ACLF II score
The Chinese Severe Hepatitis B Study Group (COSSH), based on a multicenter, open-label large cohort study, has established a novel prognostic scoring system for hepatitis B virus (HBV)-ACLF: COSSH-ACLF II s. The COSSH-ACLF II score is calculated as: 1.649×ln(INR) + 0.457×HE grade + 0.425×ln(neutrophils) + 0.396×ln(TBil) + 0.576×ln(urea) + 0.033×age. Theoretically, the score ranges from \~1.0 to \~15.0, though clinically observed values typically fall between 4.5 and 10.0. A score of less than 7.4 indicates a low-risk group, a score between 7.4 and 8.4 indicates a moderate-risk group, and a score greater than 8.4 indicates a high risk of 28- and 90-day mortality.Higher scores indicate greater severity of liver failure and a worse outcome.
Time frame: 12 weeks
Changes from the baseline in Child-Pugh score
The Child-Pugh Score assesses the prognosis of chronic liver disease based on five indicators: hepatic encephalopathy, ascites, total bilirubin, albumin, and PT/INR. The total score ranges from 5 to 15. Higher scores indicate worse liver function. (Classification: Grade A = 5-6 points; Grade B = 7-9 points; Grade C = 10-15 points.)
Time frame: 12-weeks
Change from Baseline in Clinical Symptom Score
Assessment of clinical symptoms including fatigue, anorexia, nausea, jaundice, and level of consciousness. Each symptom is graded on a scale from 0 (absent) to 3(severe). The individual scores are summed to calculate a total symptom score ranging from 0 to 15. Higher scores indicate more severe symptoms.
Time frame: 12 weeks
4-Week Survival Rate
The percentage of participants who are alive at 4 weeks after enrollment
Time frame: 4 weeks
The rate of participants with adverse outcomes at Week 4 and Week 12
The rate of adverse outcomes, defined as death, treatment abandonment, or liver transplantation.
Time frame: 4-week , 12-week
Change from Baseline in Hemoglobin
Assessment of hemoglobin concentration. Presented in units of g/L.
Time frame: Day1, Day4、Day7、Day10、Day13、Day28、Day84
Change from Baseline in International Normalized Ratio (INR)
Assessment of coagulation function via INR. INR is a standardized ratio without units. Higher values indicate worse coagulation function.
Time frame: Day1, Day4、Day7、Day10、Day13、Day28、Day84
Change from Baseline in Interleukin-6 (IL-6)
Measurement of serum Interleukin-6 concentration to evaluate the pro-inflammatory cytokine response. Presented in units of pg/mL.
Time frame: Day1, Day4、Day7、Day10、Day13、Day28、Day84
Change from Baseline in White Blood Cell (WBC) Count
Assessment of inflammation through total white blood cell count. Presented in units of 10\^9/L.
Time frame: Day1, Day4、Day7、Day10、Day13、Day28、Day84
Number of participants with treatment-related adverse Events (AEs) and serious Adverse Events (SAEs)
Safety assessment evaluating the frequency and severity of adverse events throughout the study duration. All treatment-related adverse events will be assessed by CTCAE v5.0.
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acute-On-Chronic Liver Failure →
Third Affiliated Hospital, Sun Yat-Sen University →